ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • Sjogren's syndrome and viruses
  • Sjogren's syndrome and work
  • Sjӧgrens
  • Sjӧgrens and autoantibodies
  • skeletal muscle inflammation
  • SKG
  • SKG and arthritis
  • skg mice
  • skill development and treatment
  • skin
  • skin and antibodies
  • skin and Kidney
  • skin and synovial fluid
  • skin and systemic lupus erythematosus (SLE)
  • skin and systemic sclerosis
  • skin and transcriptional regulation
  • skin and treatment
  • skin and ulcers
  • skin and uveitis
  • skin and vasculitis
  • skin and vasculogenesis
  • Skin Eruptions
  • Skin fibrosis
  • skin fibrosis and collagen
  • skin fibrosis and cyclophosphamide
  • skin fibrosis and systemic sclerosis
  • skin fibrosis and transforming growth factor
  • skin fibrosis and ultrasonography
  • Skin fibrosis and wounds
  • skin inflammation
  • Skin Macrophages and Autoimmune Skin Disease
  • SLAMF6 and Immunological Synapse
  • SLE
  • SLE and alcohol use
  • SLE and anemia
  • SLE and animal models
  • SLE and antibodies
  • SLE and antiphospholipid antibodies
  • SLE and antiphospholipid syndrome
  • SLE and apoptosis
  • SLE and ASC
  • SLE and assessment
  • SLE and atherosclerosis
  • SLE and auto-immunity
  • SLE and autoantibodies
  • SLE and azathioprine
  • SLE and belimumab
  • SLE and benchmarking tools
  • SLE and bioinformatics
  • SLE and biomarkers
  • SLE and cancer
  • SLE and cardiovascular disease
  • SLE and cerebrovascular disease
  • SLE and classification criteria
  • SLE and clinical research
  • SLE and clinical trials
  • SLE and cognitive dysfunction
  • SLE and complement
  • SLE and coronary artery disease
  • SLE and corticosteroids
  • SLE and cutaneous lupus
  • SLE and cytokines
  • SLE and depression
  • SLE and Disease Activity
  • SLE and early incomplete SLE
  • SLE and economics
  • SLE and environmental factors
  • SLE and epigenetics
  • SLE and exercise
  • SLE and family studies
  • SLE and fibromyalgia
  • SLE and gene therapy
  • SLE and genetics
  • SLE and glomerulonephritis
  • SLE and health behaviors
  • SLE and health care cost
  • SLE and health outcome
  • SLE and healthcare system
  • SLE and hydroxychloroquine
  • SLE and imaging techniques
  • SLE and immunoglobulin (IG)
  • SLE and immunosuppressants
  • SLE and infection
  • SLE and interferons
  • SLE and kinase
  • SLE and lipids
  • SLE and lupus nephritis
  • SLE and major histocompatibility complex (MHC)
  • SLE and microbiome
  • SLE and monocytes
  • SLE and morbidity and mortality
  • SLE and nephritis
  • SLE and neurologic involvement
  • SLE and neuropsychiatric disorders
  • SLE and online patient engagement
  • SLE and opioids
  • SLE and outcome measures
  • SLE and outcomes
  • SLE and patient
  • SLE and patient outcomes
  • SLE and pediatric rheumatology
  • SLE and phagocytosis
  • SLE and phenotypes
  • SLE and population studies
  • SLE and pregnancy
  • SLE and prolactin
  • SLE and psoriatic arthritis
  • SLE and quality improvement
  • SLE and quality of life
  • SLE and remission
  • SLE and renal disease
  • SLE and resveratrol
  • SLE and rituximab
  • SLE and safety
  • SLE and signal transduction
  • SLE and Sjogren's syndrome
  • SLE and skin
  • SLE and steroids
  • SLE and syk
  • SLE and systemic lupus erythematosus (SLE)
  • SLE and T cells
  • SLE and T-Regulatory Cells
  • SLE and tacrolimus
  • SLE and tertiary
  • SLE and thrombocytopenia
  • SLE and thrombosis
  • SLE and tobacco use
  • SLE and toll-like receptors
  • SLE and transcriptional regulation
  • SLE and treatment
  • SLE and tumor necrosis factor (TNF)
  • SLE and Urinary Biomarkers
  • SLE and utilization review
  • SLE and vaccines
  • SLE and Validity
  • SLE and work
  • SLEDAI
  • sleep
  • sleep and depression
  • sleep and sleep disorders
  • sleep and systemic lupus erythematosus (SLE)
  • Sleep apnea
  • sleep apnea and sleep disorders
  • Sleep disorder
  • sleep disorders and fatigue
  • sleep disorders and sleep apnea
  • sleep disorders and spondylarthropathy
  • sleep disorders and statistical methods
  • sleep disorders and systemic lupus erythematosus (SLE)
  • sleep disorders and systemic sclerosis
  • sleep disorders and therapy
  • sleep disorders and treatment
  • SLR
  • Small Airways
  • small fiber neuropathy
  • small molecules
  • small molecules and Biologics
  • small molecules and chondrocytes
  • small molecules and inflammatory cytokines
  • small molecules and spondylarthropathy
  • small molecules and tofacitinib
  • small molecules and treatment
  • small molecules and tumor necrosis factor (TNF)
  • Smartphone Application
  • Smoking
  • smoking and epidemiology
  • smooth muscle cells and epigenetics
  • SNP
  • SNPs
  • social media
  • social media and data analysis
  • social media and social support
  • social media and spondylarthritis
  • social media and steroids
  • social media and systemic lupus erythematosus (SLE)
  • social media and technology
  • social media and treatment
  • social media and website
  • Social Participation
  • Social Participation and pain
  • Social support
  • social support and stress
  • Social support and systemic lupus erythematosus (SLE)
  • social support and total joint replacement
  • socio-economic inequities
  • socio-economic inequities and socioeconomic factors
  • socio-economic inequities and spondylarthritis
  • socio-economic inequities and systemic lupus erythematosus (SLE)
  • socio-economic inequities and systemic sclerosis
  • socio-economic inequities and total joint replacement
  • socio-economic inequities and utilization review
  • socioeconomic analysis
  • socioeconomic factors
  • socioeconomic factors and job
  • socioeconomic factors and socioeconomic status
  • socioeconomic factors and surgery
  • socioeconomic factors and systemic lupus erythematosus (SLE)
  • socioeconomic factors and treatment
  • socioeconomic factors and treatment options
  • socioeconomic status
  • First |
  • « Previous Page
  • 55
  • 56
  • 57
  • 58
  • 59
  • [60]
  • 61
  • 62
  • 63
  • 64
  • 65
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology